23andMe Holding Co. - ME STOCK NEWS

23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting around 7 million users. Hackers targeted the genetic information of Jewish and Chinese customers, selling it on the dark web. Despite knowing the specifics, 23andMe did not inform affected customers about their personal data being compromised. This resulted in significant safety concerns, especially for Jewish and Chinese users. A class-action lawsuit has been filed against the company, accusing it of negligence and failing to protect user data. The law firm Levi & Korsinsky is investigating potential compensation for affected users.

In December 2023, 23andMe (NASDAQ:ME) faced a significant data breach, impacting about 7 million users. Hackers specifically targeted personal genetic data of Jewish and Chinese customers. This sensitive information was sold on the dark web, a detail that 23andMe reportedly hid from affected users. The breach's severity is highlighted by a class action lawsuit claiming that over 1 million Jewish customers' data was leaked following an Israel-Hamas conflict and 350,000 Chinese customers' data was released on request. The lawsuit accuses 23andMe of failing to notify all compromised users or disclose the targeting of Jewish and Chinese customers. The breach has raised serious safety concerns, especially regarding the Chinese government's potential actions against its citizens.

23andMe (Nasdaq: ME) has launched a new genetic report for Bipolar Disorder, targeted at 23andMe+ Premium members. This report uses a polygenic risk score (PRS) model to determine an individual's likelihood of developing bipolar disorder based on thousands of genetic variants, ancestry, and birth sex. Bipolar disorder affects about 4.4% of American adults, and genetics are a significant contributing factor. This new report, developed from 23andMe's proprietary research database, aims to help users identify potential symptoms early and manage their mental health better. It follows other mental health PRS reports such as Anxiety, Panic Attacks, and Depression.

23andMe (NASDAQ:ME) was hacked in December 2023, compromising the data of approximately 7 million users. The breach specifically targeted Jewish and Chinese users, whose personal genetic information was sold on the dark web. The lawsuit claims that 23andMe did not inform users about the targeted nature of the breach and the sale of their data. The hacker, using the alias 'Golem,' leaked lists of Jewish and Chinese users in retaliation for current events, including the Israel-Hamas conflict. The company has been accused of shifting blame to users for using recycled passwords and failing to report the full extent of the breach promptly. Levi & Korsinsky, LLP is investigating potential compensation for affected customers.

23andMe Therapeutics has announced positive preliminary Phase 2 results for 23ME-00610, an anti-CD200R1 antibody, at the 2024 ASCO Annual Meeting. The study showed a confirmed partial response in a patient with pancreatic neuroendocrine cancer and qualitative clinical benefit in an ovarian cancer patient. The treatment demonstrated acceptable safety and tolerability, meeting the specified pharmacology targets at 1400 mg dosed every three weeks. Over 70% of patients had detectable CD200 in their tumors, suggesting it as a potential biomarker. The study involved 32 patients with advanced neuroendocrine and ovarian cancers, highlighting promising safety profiles and potential anti-cancer effects. No severe treatment-emergent adverse events were reported, and immune-related adverse events remained mild. More research is needed to solidify these findings and explore combination therapy possibilities.

23andMe (NASDAQ:ME) faced a significant data breach in December 2023, affecting 7 million users. A recent class action complaint reveals that hackers targeted the genetic information of Jewish and Chinese customers, selling this data on the dark web. The breach was allegedly hidden from affected users by the company, who did not disclose the specific targeting of Jewish and Chinese users. The data leak occurred on October 1, 2023, and included sensitive information such as phenotype and health data. This incident has led to significant safety concerns for the affected individuals. Legal firm Levi & Korsinsky, LLP is investigating the breach and potential compensation for affected users.

23andMe (NASDAQ:ME) suffered a significant data breach in December 2023, impacting approximately 7 million users. Recent revelations from a class-action lawsuit indicate that hackers specifically targeted the genetic information of Jewish and Chinese customers, which the company allegedly concealed from the affected users. The hackers leaked lists of this sensitive information on the dark web, posing significant security risks to those individuals. 23andMe has been criticized for its delayed and incomplete disclosure of the breach's extent, and the lawsuit seeks compensation for those affected.

23andMe, in collaboration with The Michael J. Fox Foundation for Parkinson’s Research, conducted the largest study on the LRRK2 G2019S variant, revealing new insights into Parkinson’s disease. The study, launched in 2018, included 1,286 carriers and 109,154 non-carriers over 3.5 years. Findings indicate that LRRK2 carriers are seven times more likely to develop Parkinson’s but experience milder symptoms and slower disease progression compared to non-carriers. The research also uncovered genetic hotspots in Mexico, Cuba, Puerto Rico, and Brazil, linking them to historical migrations of Jewish populations. Results published in the June 2024 issue of Brain highlight the need for more sensitive early detection criteria for LRRK2 carriers.

23andMe Holding Co. (Nasdaq: ME) reported its FY24 Q4 and full-year results on May 23, 2024. Key highlights include a 31% decrease in Q4 revenue to $64 million and a 27% decline in full-year revenue to $220 million, primarily due to lower consumer services and research revenue. The company formed a Special Committee to review strategic alternatives and acknowledged CEO Anne Wojcicki's interest in acquiring outstanding shares. Operating expenses surged to $239 million in Q4, driven by a $153 million goodwill impairment charge. The net loss for Q4 was $209 million, and $667 million for the full year. However, the company advanced its clinical trials and launched new products. FY2025 guidance was not provided due to the ongoing strategic review.